PE20040242A1 - Un derivado de piridina opticamente activo y un medicamento que lo contiene - Google Patents

Un derivado de piridina opticamente activo y un medicamento que lo contiene

Info

Publication number
PE20040242A1
PE20040242A1 PE2003000253A PE2003000253A PE20040242A1 PE 20040242 A1 PE20040242 A1 PE 20040242A1 PE 2003000253 A PE2003000253 A PE 2003000253A PE 2003000253 A PE2003000253 A PE 2003000253A PE 20040242 A1 PE20040242 A1 PE 20040242A1
Authority
PE
Peru
Prior art keywords
pyridine derivative
agent
optically active
product containing
medicinal product
Prior art date
Application number
PE2003000253A
Other languages
English (en)
Inventor
Kevin Bacon
Kinji Fuchikami
Keiko Fukushima
Rolf Grosser
Yuji Koriyama
Takashi Yoshino
Toshiki Murata
Noriko Nunami
Sachiko Sasaki
Hiroki Sato
Megumi Yamauchi
Timothy Lowinger
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of PE20040242A1 publication Critical patent/PE20040242A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIERE A UN DERIVADO DE PIRIDINA, CONSTITUIDO POR (-)-7-[2-(CICLOPROPILMETOXI)-6-HIDROXIFENIL]-5-[(3S)-3-PIPERIDINIL]-1,4-DIHIDRO-2H-PIRIDO[2,3-d][1,3]OXAZIN-2-ONA DE FORMULA (I) QUE TIENE UNA PUREZA OPTICA DE AL MENOS UN 90% DE EXCESO ENANTIOMERICO. UNA COMPOSICION FARMACEUTICA QUE LO CONTIENE. EL COMPUESTO ES UN INHIBIDOR DE LA QUINASA IkB Y ES UTIL PARA EL TRATAMIENTO Y PROFILAXIS DE EFERMEDADES QUE IMPLICAN LA ACTIVIDAD DE NF-kB, Y ACTUA COMO: a) UN AGENTE ANTIINFLAMATORIO UTIL PARA TRATAR O PREVENIR UNA ENFERMEDAD SELECCIONADA DEL GRUPO CONSTITUIDO POR ASMA,RINITIS ALERGICA, DERMATITIS ATOPICA, URTICARIA, CONJUNTIVITIS, CATARRO PRIMAVERAL, ARTROREUMATISMO CRONICO, LUPUS ERITEMATOSO SISTEMICO,PSORIASIS, COLITIS DIABROTICA,SINDROME DE RESPUESTA INFLAMATORIA SISTEMICA (SIRS), ENTRE OTROS. b) UN INMUNOSUPRESOR; c) UN AGENTE PARA TRATAR ISQUEMIA; d) UN AGENTE ANTITUMORAL
PE2003000253A 2002-03-14 2003-03-13 Un derivado de piridina opticamente activo y un medicamento que lo contiene PE20040242A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2002070655A JP2003277383A (ja) 2002-03-14 2002-03-14 光学活性ピリジン誘導体およびそれを含む医薬

Publications (1)

Publication Number Publication Date
PE20040242A1 true PE20040242A1 (es) 2004-05-15

Family

ID=27800344

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000253A PE20040242A1 (es) 2002-03-14 2003-03-13 Un derivado de piridina opticamente activo y un medicamento que lo contiene

Country Status (13)

Country Link
US (2) US7375103B2 (es)
EP (1) EP1487842B1 (es)
JP (2) JP2003277383A (es)
AR (1) AR038950A1 (es)
AU (1) AU2003215624A1 (es)
CA (1) CA2478942A1 (es)
DE (1) DE60312494T2 (es)
ES (1) ES2283795T3 (es)
HN (1) HN2003000098A (es)
PE (1) PE20040242A1 (es)
TW (1) TW200403247A (es)
UY (1) UY27719A1 (es)
WO (1) WO2003076447A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005036655A1 (de) * 2005-08-04 2007-02-08 Bayer Healthcare Ag Behandlung von Tumoren mit IKK-ß Inhibitoren
US8426355B2 (en) 2006-03-15 2013-04-23 Theralogics, Inc. Methods of treating muscular wasting diseases using NF-κB activation inhibitors
WO2008044339A1 (fr) * 2006-10-13 2008-04-17 Aqumen Biopharmaceuticals K.K. Agent thérapeutique/de prévention contenant un composé de statine, utilisé pour une maladie intraoculaire
CN104491864A (zh) 2008-04-21 2015-04-08 奥德纳米有限公司 用于治疗耳部疾病和病况的耳用调配物及方法
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
AP2015008750A0 (en) * 2013-04-08 2015-09-30 Bayer Pharma AG Use of substituted 2,3-dihydroimidazo[1,2-c] quinazolines for treating lymphomas
US20180289685A1 (en) 2015-04-30 2018-10-11 Bayer Pharma Aktiengesellschaft Combinations of inhibitors of irak4 with inhibitors of btk
WO2017148902A1 (de) 2016-03-03 2017-09-08 Bayer Pharma Aktiengesellschaft Neue 2-substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
AU2017290256A1 (en) 2016-06-29 2019-01-17 Otonomy, Inc. Triglyceride otic formulations and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4272338B2 (ja) * 2000-09-22 2009-06-03 バイエル アクチェンゲゼルシャフト ピリジン誘導体

Also Published As

Publication number Publication date
TW200403247A (en) 2004-03-01
DE60312494T2 (de) 2007-11-29
WO2003076447A1 (en) 2003-09-18
JP2003277383A (ja) 2003-10-02
HN2003000098A (es) 2003-12-15
UY27719A1 (es) 2003-10-31
DE60312494D1 (de) 2007-04-26
EP1487842B1 (en) 2007-03-14
US20050215547A1 (en) 2005-09-29
EP1487842A1 (en) 2004-12-22
JP2005526074A (ja) 2005-09-02
AR038950A1 (es) 2005-02-02
CA2478942A1 (en) 2003-09-18
US7375103B2 (en) 2008-05-20
ES2283795T3 (es) 2007-11-01
AU2003215624A1 (en) 2003-09-22
US20090054424A1 (en) 2009-02-26

Similar Documents

Publication Publication Date Title
DOP2006000170A (es) Nuevos derivados de espirocromanona
NO20083561L (no) Forbindelser for behandling av inflammatoriske forstyrrelser
NO20083567L (no) Hydantoinderivater for behandling av inflammatoriske forstyrrelser
SV2010003706A (es) 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas
CO6220955A2 (es) Una composicion farmaceutica que contiene (a) n1-(5-cloropiridin-2-il)-n2-((1s,2r,4s)-4-[dimetilamino)carbonil]-2-{[(5-metil-4,5,6,7-tetrahidrotiazol[5,4-c]piridin-2-il) carbonil] amino} coclohexil)etanodiamida
DOP2010000064A (es) 2-anilinopurin 8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos proliferativos
DK1485080T3 (da) Anvendelse af adapalen til behandling af dermatologiske sygdomme
PE20040242A1 (es) Un derivado de piridina opticamente activo y un medicamento que lo contiene
PE20060464A1 (es) Composicion farmaceutica que comprende flibanserina para el tratamiento de trastornos sexuales
WO2008132138A9 (en) AMINOPYRIMIDINE DERIVATIVES DISUBSTITUTED IN 4 AND 6
BRPI0414581C1 (pt) composto, composição farmacêutica compreendendo o referido composto e uso do referido composto
AR062980A1 (es) Composiciones farmaceuticas de compuestos de pirimidil-amino-benzamida
CL43596B (es) Compuestos derivados de pirimidina; composicion farmaceutica; y su uso para tratar o prevenir un trastorno o enfermedad relacionado con la actividad de crth2, tales como asma, rinitis alergica, dermatitis, atopica y conjuntivitis alergica.
ECSP067044A (es) Compuestos para el tratamiento de trastornos inflamatorios
CR10455A (es) Compuestos farmaceuticos
AR057849A1 (es) Dialurrea para el tratamiento de hipertension pulmonar
AR088195A1 (es) Composiciones farmaceuticas de n-metil-2-[3-(e)-2-piridin-2-il-vinil)-1h-indazol-6-ilsulfanil]-benzamida
PE20130009A1 (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana
SV2008003045A (es) Aminotetrahidropiranos como inhibidores de dipertidil, peptidasa-iv para el tratamiento o prevencion de diabetes
ECSP12012171A (es) Composiciones farmacéuticas del compuesto espiro-oxindol para administración tópica y sus usos como agentes terapéuticos
PE20142318A1 (es) Formulaciones de (+)-2-[1-(3-etoxi-4-metoxi-fenil)-2-metansulfonil-etil]-4-acetilaminoisoindolin-1,3-diona
DOP2012000058A (es) Agente terapeutico para trastornos del estado de animo
EA201690072A1 (ru) Состав, содержащий гиполипидемическое средство
CU20150084A7 (es) Derivados del ácido 4-((1,1) bisfenil -4-il)-3-(3-fosfonopropanamido)butanoico,activo como inhibidores de nep(endopeptidasa neutral)
CU24619B1 (es) Letermovir amorfo y formulaciones farmacéuticas sólidas del mismo para administración por via oral

Legal Events

Date Code Title Description
FA Abandonment or withdrawal